ASCO 2007 atacicept B-CLL poster

ASCO 2007 atacicept B-CLL abstract

ACR 2006 atacicept RA abstract

ACR 2006 atacicept SLE abstract

Clinical Trials Overview for Atacicept

ZymoGenetics and partner Merck Serono are conducting clinical trials with atacicept in a number of indications- general systemic lupus erythematosus (SLE), lupus nephritis, rheumatoid arthritis (RA), and advanced B-cell cancers. The companies have completed Phase 1b clinical trials in those indications, demonstrating safety, half-life and effects on B-cell function consistent with preclinical studies.

Atacicept as a potential treatment for autoimmune diseases

In 2006, the companies reported findings from the SLE and RA clinical trials and began a Phase 2 trial with atacicept in patients with rheumatoid arthritis. In October 2007, the companies received a Special Protocol Assessment from the FDA for a pivotal study with atacicept in lupus nephritis.

Atacicept as a potential treatment for B cell cancers

A clinical study is being conducted to evaluate the safety and pharmacokinetics of multiple doses of atacicept in patients with chronic lymphocytic leukemia. In 2006, the companies reported results from Phase 1b trials in multiple myeloma and non-Hodgkin's lymphomas.

If you're interested in learning more about clinical trials with atacicept, please contact us at: clinicaltrials@zgi.com.

For more information about atacicept

Product Backgrounder:
www.zymogenetics.com/products/taci-ig.html

Related Press Releases:

Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple Sclerosis

ZymoGenetics and Merck Serono Initiate Phase 2/3 Clinical Trial of Atacicept in Lupus Nephritis

ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis

ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus Nephritis

ZymoGenetics and Serono Begin Phase 2 Clinical Trial With Atacicept in Rheumatoid Arthritis

ZymoGenetics Presents Results From Two Atacicept Phase 1b Clinical Trials in B-Cell Cancer

ZymoGenetics and Serono Report Detailed Positive Results From Atacicept Phase 1b Clinical Trial in Patients With Lupus

ZymoGenetics Releases Preliminary Findings From Atacicept (TACI-Ig) Phase 1b Studies in Patients With Lupus

ZymoGenetics and Serono Present Positive Results of TACI-Ig Phase 1b Trial in Rheumatoid Arthritis at EULAR Meeting

ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis

ZymoGenetics and Serono to Begin TACI-Ig Clinical Studies in B-Cell Malignancies

Scientific Publications:
http://www.zymogenetics.com/research/publication.html